GlassScriptPhysician profile
Yeshika Sharma
NPI 1679987994
$24,187.90
in general payments reported to CMS, 2019-2025
14 companies · $8,629 in 2025
The $8,629 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,258 · 2023: $9,943 · 2024: $4,359 · 2025: $8,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,505 · Consulting Fee: $3,628 · Food and Beverage: $1,220 · Honoraria: $880 · Travel and Lodging: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,504.81 |
| Consulting Fee | $3,627.50 |
| Food and Beverage | $1,219.53 |
| Honoraria | $880.00 |
| Travel and Lodging | $698.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $14,927.11 | 2022-2025 | Ocaliva |
| Novo Nordisk INC | $8,307.16 | 2024-2025 | Wegovy |
| Abbvie INC. | $235.40 | 2023-2025 | Mavyret |
| Ipsen Biopharmaceuticals, INC | $169.35 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Genzyme Corporation | $108.33 | 2022 | |
| Janssen Scientific Affairs, LLC | $102.24 | 2022 | |
| Madrigal Pharmaceuticals | $44.16 | 2024 | Resmetirom |
| Mirum Pharmaceuticals, INC. | $43.63 | 2024-2025 | Livmarli |
| Orphalan INC | $30.22 | 2025 | Cuvrior |
| Gilead Sciences, INC. | $27.74 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.81 | 2023 | Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.25 | 2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $16.50 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yeshika Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.